drugset
drugset / Trial / NCT06684158

Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC

NCT06684158 ↗

Phase 2 Not yet recruiting 70 enrolled The First Affiliated Hospital with Nanjing Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a prospective, randomized ，multicencter, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery. The purpose of this study is to assess the safety and efficacy of Mecapegfilgrastim Combined With Adebrelimab and 5- fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT)） as Neoadjuvant Therapy in Resectable gastric and gastroesophageal junction cancer

Timeline

Start
2024-11-30
Primary completion
2027-03-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mecapegfilgrastim Protein / enzyme biologic 6 mg —
Background Adebrelimab Monoclonal antibody 1200 mg Intravenous
Background Docetaxel Small molecule 50 mg/m2 Intravenous
Background Leucovorin Small molecule 200 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background fluorouracil Small molecule 2600 mg/m2 Intravenous

Indications

gastroesophageal junction adenocarcinoma